Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Galapagos NV (GLPG)

Galapagos NV (GLPG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,197,828
  • Shares Outstanding, K 54,820
  • Annual Sales, $ 375,370 K
  • Annual Income, $ -34,550 K
  • 60-Month Beta 1.57
  • Price/Sales 14.63
  • Price/Cash Flow N/A
  • Price/Book 5.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.29
  • Number of Estimates 4
  • High Estimate 0.28
  • Low Estimate -0.90
  • Prior Year 0.34
  • Growth Rate Est. (year over year) -185.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
222.78 +18.52%
on 01/31/20
264.03 unch
on 02/18/20
+36.34 (+15.96%)
since 01/17/20
3-Month
183.02 +44.26%
on 11/19/19
264.03 unch
on 02/18/20
+75.55 (+40.08%)
since 11/18/19
52-Week
94.75 +178.66%
on 03/27/19
264.03 unch
on 02/18/20
+160.91 (+156.04%)
since 02/15/19

Most Recent Stories

More News
Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat

Gilead's (GILD) earnings fall short of estimates but sales beat the same in the fourth quarter of 2019.

GSK : 43.55 (-0.43%)
GILD : 67.01 (-0.81%)
GLPG : 264.03 (+1.95%)
KNSA : 17.95 (+3.58%)
Vertex (VRTX) Hits 52-Week High, Can the Run Continue?

Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

VRTX : 245.93 (+0.87%)
GLPG : 264.03 (+1.95%)
VNDA : 13.37 (+5.28%)
EIDX : 51.00 (-2.22%)
Orphan Drug Designation for GLPG1690 in systemic sclerosis

Mechelen, Belgium; 29 January 2020, 8.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces today that the US Food & Drug Administration (FDA) and the European Commission (EC) have granted investigational...

GLPG : 264.03 (+1.95%)
Galapagos appoints Michele Manto as Chief Commercial Officer

Galapagos is preparing to deliver its first medicine to patients

GLPG : 264.03 (+1.95%)
Fibrocor and Galapagos sign expanded collaboration in fibrosis

Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on...

GLPG : 264.03 (+1.95%)
Galapagos completes recruitment of PINTA trial in idiopathic pulmonary fibrosis

Mechelen, Belgium; 13 January 2020, 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) has completed recruitment for the PINTA Phase 2 clinical trial with oral GPR84 inhibitor GLPG1205.

GLPG : 264.03 (+1.95%)
Gilead holds 25.84% of Galapagos shares

Mechelen, Belgium; 9 January 2020; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Gilead Sciences, Inc.

GLPG : 264.03 (+1.95%)
GILD : 67.01 (-0.81%)
Galapagos to present at 38th Annual J.P. Morgan Healthcare Conference

Mechelen, Belgium; 9 January 2020, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 38th Annual J.P. Morgan Healthcare Conference on January 14-16, 2020.

GLPG : 264.03 (+1.95%)
JPM : 135.64 (-1.32%)
Gilead (GILD) Partners With Eisai for RA Candidate in Japan

Gilead Sciences (GILD) collaborates with Eisai for the distribution and co-promotion of its rheumatoid arthritis candidate, filgotinib. The companies will jointly commercialize the drug, if approved.

GSK : 43.55 (-0.43%)
ALXN : 102.16 (-0.39%)
GILD : 67.01 (-0.81%)
GLPG : 264.03 (+1.95%)
Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib

Gilead (GILD) files an NDA for filgotinib with the FDA for the treatment of adults with moderate-to-severe rheumatoid arthritis.

LLY : 141.01 (-0.08%)
ALKS : 17.61 (-0.90%)
GILD : 67.01 (-0.81%)
GLPG : 264.03 (+1.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade GLPG with:

Business Summary

Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include...

See More

Key Turning Points

2nd Resistance Point 266.14
1st Resistance Point 265.09
Last Price 264.03
1st Support Level 261.92
2nd Support Level 259.80

See More

52-Week High 264.03
Last Price 264.03
Fibonacci 61.8% 199.37
Fibonacci 50% 179.39
Fibonacci 38.2% 159.41
52-Week Low 94.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar